Skip to main content
    G

    Guardian Pharmacy Services, Inc. (GRDN)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NYSE

    $49.42
    -0.09 (-0.19%)

    Market Cap: $3.14B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Guardian Pharmacy Services, Inc. (GRDN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Guardian Pharmacy Services (GRDN) to earn $1.36 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.45B. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 7 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy114.3%
    Buy685.7%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    7

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 10.3% and revenue estimates rise 6.9%.

    Fiscal year ending Dec 31, 2026
    $1.36
    EPS consensus, revenue $1.45B
    Fiscal year ending Dec 31, 2027
    $1.50
    EPS consensus, revenue $1.55B
    Next report
    Mar 9, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.36$1.30 to $1.397$1.45B$1.45B to $1.46B7
    Dec 31, 2027$1.50$1.41 to $1.587$1.55B$1.52B to $1.60B7

    Quarterly Estimates

    The EPS consensus falls from $0.41 for the quarter ending Dec 31, 2026 to $0.29 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.41$0.36 to $0.479$404.14M$383.08M to $441.02M9
    Mar 31, 2027$0.29$0.26 to $0.305$362.03M$354.40M to $371.89M5

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 12 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202670
    Fiscal year ending Dec 31, 202750

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.6% from $1.30.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$1.36$1.30$1.30$1.30$1.30+4.7%
    Fiscal year ending Dec 31, 2027$1.50$1.43$1.43$1.43$1.43+4.6%
    Quarter ending Mar 31, 2027$0.29$0.29$0.29$0.28$0.28+3.6%

    Frequently Asked Questions About GRDN

    What is the GRDN stock forecast?

    Consensus analyst estimates put Guardian Pharmacy Services's EPS at $1.36 for the fiscal year ending Dec 31, 2026, on revenue of $1.45B. The consensus rating from 7 analysts is Buy.

    How do analysts rate GRDN stock?

    Of 7 analysts covering Guardian Pharmacy Services, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from GRDN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.36, with estimates from $1.30 to $1.39 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.50, with estimates from $1.41 to $1.58 from 7 analysts.

    What revenue do analysts expect from Guardian Pharmacy Services next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.45B, with estimates from $1.45B to $1.46B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.55B, with estimates from $1.52B to $1.60B.

    How many analysts cover GRDN?

    7 analysts rate Guardian Pharmacy Services stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.